Samsung Medison, a major affiliate of Samsung Electronics specializing in medical equipment, has announced its acquisition of all shares of Sonio SAS, a fatal ultrasound AI software firm established in 2020 to improve global women and children’s health through innovative medical solutions. Sonio, known for its AI-assisted obstetrics and gynaecology ultrasound IT solutions, developed the FDA 510 [k] approved Sonio Detect, which uses deep learning to enhance image quality and clinical accuracy in real-time.
After the acquisition, Sonio will maintain its independence, with its headquarters in France, continuing its growth and ensuring its products remain compatible with all ultrasound device manufacturers. This partnership will combine Samsung Medison’s advanced ultrasound technology with Sonio’s AI expertise to enhance prenatal care through innovative AI workflows and accelerated patient outcome improvements.
Yong Kwan Kim, CEO of Samsung Medison, expressed admiration for Sonio’s contributions to maternal care and highlighted the acquisition’s role in fulfilling Samsung’s mission to enhance life quality through technology. Cécile Brosset, CEO of Sonio, sees this partnership as an opportunity for growth and innovation while maintaining Sonio’s independence and focus on advancing medical reporting and diagnostic software worldwide, including in underserved healthcare regions.
The transaction’s completion depends on regulatory approvals, including that of the French Ministry of the Economy and Finance.
